Work

Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer

Year: 2025

Type: article

Abstract: Purpose: Present a case of Mirvetuximab soravtansine (MIRV)-induced intraepithelial corneal deposits, review a proposed mechanism to explain the blurred vision our patient experienced, and explain clinical exams that may be used to support the diagnosis. Observations: A 63-year-old female with metastatic ovarian cancer diagnosed with intraepithelial corneal deposits two weeks after her first MIRV infusion. Treatment with topical prednisolone acetate 1 % ophthalmic suspension and lubricating eye drops without interruption of her MIRV infusions resulted in complete resolution of blurry vision and corneal deposits. Conclusions and importance: The natural reversibility of MIRV-induced keratopathies underscores the need for prompt and regular ophthalmic assessments throughout drug administration. Understanding the mechanism behind these corneal changes, how to recognize them in a clinical setting, and expedite their reversal are essential to improve quality-of-life metrics in patients receiving MIRV transfusions.

Source: American Journal of Ophthalmology Case Reports

DOI: 10.1016/j.ajoc.2025.102271

Authors: Charlotte McRae, Rachael Cowan, Macy Green, Jack S. Parker

Institutions: University of Alabama at Birmingham, UAB Medicine

Language: English

Topic: Drug-Induced Ocular Toxicity

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,590